Table 1 Characteristics and outcomes of patients who underwent magnetic compression anastomosis for biliary complications after living-donor liver transplantation
Years | Author | No. | Age (years) | Sex | Disease | Reconstruction | Biliary complication | Intervention | Distance (mm) | Duration from LDLT (months) | Period until removal of magnet (days) | Duration of internal catheter (weeks) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2005 | Muraoka et al. [15] | 1 | 1 | F | FH | R-Y | Stricture | CJS | N/A | 6 | 12 | 8 | Success |
2 | 57 | M | LC | R-Y | Stricture | CJS | N/A | 7 | 12 | 8 | Success | ||
2005 | Okajima et al. [16] | 3 | 44 | F | FH | D-D | Obstruction | CCS | N/A | 12 | 42 | 12 | Success |
2008 | Akita et al. [17] | 4 | 34 | F | N/A | D-D | Obstruction | CCS | 5 | 0 | 21 | 0 | Success |
2008 | Mita et al. [18] | 5 | 0.5 | F | FH | R-Y | Obstruction | CJS | N/A | 1.5 | 12 | N/A | Success |
6 | 59 | F | LC | R-Y | Obstruction | CJS | N/A | 5 | 25 | N/A | Success | ||
2009 | Matsuno et al. [19] | 7 | 53 | M | N/A | D-D | Stricture | CCS | 3 | N/A | 10 | 4.3 | Success |
2010 | Marubashi et al. [13] | 8 | 53 | M | LC (HBV) | D-D | Dehiscence | CCS | N/A | 6 | 63 | 72 | Success |
2010 | Itoi et al. [20] | 9 | 60 | M | N/A | D-D | Obstruction | CCS | N/A | 18 | 9 | 24 | Success |
2011 | Kawakubo et al. [6] | 10 | 56 | M | LC (HCV) | R-Y | Obstruction | CJS | N/A | 9 | 23 | 56 | Success |
2011 | Jang et al. [14] | 11 | 63 | F | LC (HBV) | D-D | Stricture | CCS | N/A | 71 | 42 | 83 | Success |
12 | 49 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 6 | 26 | 70 | Success | ||
13 | 54 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 55 | 18 | 49 | Success | ||
14 | 64 | F | LC (HBV) | D-D | Stricture | CCS | N/A | 71 | 71 | 14 | Success | ||
15 | 54 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 15 | 102 | 26.7 | Success | ||
16 | 48 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 13 | 102 | 25.7 | Success | ||
17 | 63 | F | Liver failure (drug) | D-D | Stricture | CCS | 30 | 107 | – | – | Failure | ||
18 | 33 | M | Liver failure (HAV) | D-D | Stricture | CCS | N/A | 5 | 33 | 26.7 | Success | ||
19 | 61 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 4 | 14 | 25.4 | Success | ||
20 | 54 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 9 | 181 | 7.3 | Success | ||
21 | 52 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 1 | 153 | N/A | Success | ||
22 | 51 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 5 | – | – | Failure | ||
2014 | Uemura et al. [21] | 23 | 49 | F | LC (HCV) | D-D | Obstruction | CCS | 11 | 11 | 24 | 13 | Success |
2016 | Ersoz et al. [22] | 24 | 37 | M | LC (HBV) | D-D | Dehiscence | CCS | 15 | 12 | 13 | N/A | Success |
25 | 54 | F | LC (HBV, HDV) | D-D | Dehiscence | CCS | 10 | 84 | 14 | N/A | Success | ||
26 | 53 | F | LC (HCV) | D-D | Dehiscence | CCS | 10 | 14 | 42 | N/A | Success | ||
27 | 63 | M | LC (HBV) | D-D | Dehiscence | CCS | 5 | 7 | 18 | N/A | Success | ||
28 | 68 | F | LC (HBV) | D-D | Dehiscence | CCS | 10 | 6 | 22 | N/A | Success | ||
29 | 54 | M | LC (HBV) | D-D | Dehiscence | CCS | 15 | 7 | 13 | N/A | Success | ||
2017 | Saito et al. [23] | 30 | 54 | F | LC (PSC) | R-Y | Strangulated ileus | CDS | 27 | 60 | 25 | 44 | Success |
2017 | Parlak et al. [24] | 31 | 68 | F | LC (HCV) | D-D | Obstruction | CCS | 2.5 | 14 | 7 | 36 | Success |
32 | 52 | M | LC (HBV) | D-D | Obstruction | CCS | 3 | 22 | 10 | N/A | Success | ||
33 | 55 | M | LC (HBV) | D-D | Obstruction | CCS | 4 | 16 | 2 | 36 | Success | ||
34 | 58 | M | LC (Cryptogenic) | D-D | Obstruction | CCS | 6 | 34 | 14 | 48 | Success | ||
35 | 38 | F | LC (HBV) | D-D | Obstruction | CCS | 3 | 38 | 12 | 48 | Success | ||
36 | 63 | F | LC (HCV) | D-D | Obstruction | CCS | 3 | 13 | 2 | 44 | Success | ||
37 | 52 | M | LC (HBV) | D-D | Obstruction | CCS | 4 | 60 | 10 | N/A | Success | ||
38 | 54 | M | LC (HBV) | D-D | Obstruction | CCS | 5 | 15 | – | – | Failure | ||
39 | 62 | M | LC (Cryptogenic) | D-D | Obstruction | CCS | 5 | 5 | – | – | Failure | ||
2018 | Kubo | 40 | 55 | F | LC (PSC) | R-Y | Dehiscence | CJS | 10 | 12 | 21 | 48 | Success |
Dehiscence | CJS | 10 | 14 | 47 | 76 | Success | |||||||
Mean | 51.6 | s | 8.9 | 22.6 | 35.5 | 37.6 | 36/40(90.0%) |